PT1121104E - Novas formulacoes orais de libertacao controlada - Google Patents
Novas formulacoes orais de libertacao controladaInfo
- Publication number
- PT1121104E PT1121104E PT99950595T PT99950595T PT1121104E PT 1121104 E PT1121104 E PT 1121104E PT 99950595 T PT99950595 T PT 99950595T PT 99950595 T PT99950595 T PT 99950595T PT 1121104 E PT1121104 E PT 1121104E
- Authority
- PT
- Portugal
- Prior art keywords
- oral formulations
- new oral
- controlled liberation
- controlled
- liberation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9821298.8A GB9821298D0 (en) | 1998-10-01 | 1998-10-01 | Organic compoundsq |
GBGB9821299.6A GB9821299D0 (en) | 1998-10-01 | 1998-10-01 | Organic compounds |
GBGB9826654.7A GB9826654D0 (en) | 1998-12-03 | 1998-12-03 | Organic compounds |
GBGB9827624.9A GB9827624D0 (en) | 1998-12-16 | 1998-12-16 | Organic compounds |
GBGB9907822.2A GB9907822D0 (en) | 1999-04-06 | 1999-04-06 | Organic compounds |
GBGB9907823.0A GB9907823D0 (en) | 1999-04-06 | 1999-04-06 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1121104E true PT1121104E (pt) | 2005-05-31 |
Family
ID=27547321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99950595T PT1121104E (pt) | 1998-10-01 | 1999-10-01 | Novas formulacoes orais de libertacao controlada |
Country Status (23)
Country | Link |
---|---|
US (5) | US20010033866A1 (pt) |
EP (1) | EP1121104B1 (pt) |
JP (1) | JP4012689B2 (pt) |
KR (1) | KR100603900B1 (pt) |
CN (1) | CN1406126A (pt) |
AT (1) | ATE286725T1 (pt) |
AU (1) | AU764866B2 (pt) |
BR (1) | BR9914251A (pt) |
CA (1) | CA2342340C (pt) |
CZ (1) | CZ302888B6 (pt) |
DE (1) | DE69923200T2 (pt) |
ES (1) | ES2237163T3 (pt) |
HK (1) | HK1052473A1 (pt) |
HU (1) | HUP0103883A3 (pt) |
ID (1) | ID27504A (pt) |
IL (2) | IL141762A0 (pt) |
NO (1) | NO331689B1 (pt) |
NZ (1) | NZ510683A (pt) |
PL (1) | PL196945B1 (pt) |
PT (1) | PT1121104E (pt) |
SK (1) | SK285250B6 (pt) |
TR (1) | TR200100931T2 (pt) |
WO (1) | WO2000019985A2 (pt) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100603900B1 (ko) * | 1998-10-01 | 2006-07-25 | 노파르티스 아게 | 신규의 서방성 경구 제제 |
JP5558648B2 (ja) * | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
CA2380333A1 (en) * | 1999-08-26 | 2001-03-01 | Christian Andina | Pharmaceutical formulations |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
SK287066B6 (sk) * | 2000-09-29 | 2009-11-05 | Solvay Pharmaceuticals B. V. | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
JP5023412B2 (ja) * | 2001-05-09 | 2012-09-12 | 吉澤石灰工業株式会社 | ホルムアルデヒド廃液の処理剤 |
PT1424997E (pt) * | 2001-09-14 | 2008-02-28 | Scolr Inc | Forma de dosagem de libertação prolongada modulada por aminoácidos |
JP2005525299A (ja) * | 2001-09-14 | 2005-08-25 | スコラー インコーポレイテッド | アミノ酸調節性の長期放出投薬形態 |
KR100453288B1 (ko) * | 2002-03-12 | 2004-10-21 | 한국화학연구원 | 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치 |
CA2494585A1 (en) * | 2002-08-07 | 2004-02-19 | Novartis Ag | Methods for the treatment of dementia based on apo e genotype |
WO2004089427A1 (en) * | 2003-04-07 | 2004-10-21 | Jurox Pty Ltd | Stable carprofen composition |
WO2004100929A1 (en) * | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
MEP3608A (en) * | 2003-08-08 | 2011-05-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
US20100129310A1 (en) * | 2004-08-09 | 2010-05-27 | Pavak Rajnikanth Mehta | Stabilized desloratadine composition |
ES2403069T3 (es) * | 2005-02-22 | 2013-05-13 | Sun Pharma Advanced Research Company Ltd | Composición oral de liberación controlada que contiene levetiracetam |
US20060263427A1 (en) * | 2005-05-03 | 2006-11-23 | Roberts Richard H | Quinine formulations |
EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
GB0606562D0 (en) * | 2006-03-31 | 2006-05-10 | Novartis Ag | Organic compounds |
JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
AU2008232419B2 (en) | 2007-04-02 | 2013-06-20 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
ITMI20071502A1 (it) * | 2007-07-25 | 2009-01-26 | Archimica Srl | Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento |
WO2009022345A1 (en) * | 2007-08-14 | 2009-02-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Phenyl carbamates for the treatment of multiple sclerosis |
PL2187742T3 (pl) | 2007-08-23 | 2018-06-29 | Theracos Sub, Llc | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy |
EP2197454A4 (en) * | 2007-09-25 | 2012-07-04 | Idexx Lab Inc | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES |
US20110201597A1 (en) | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
TWI523652B (zh) | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
AR073118A1 (es) | 2008-08-22 | 2010-10-13 | Theracos Inc | Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo. |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
MX2012003207A (es) | 2009-09-18 | 2012-05-29 | Chase Pharmaceuticals Corp | Metodo y composicion para tratar la demencia de tipo alzheimer. |
US20110150986A1 (en) * | 2009-12-18 | 2011-06-23 | Kristin Arnold | Quinine formulations, method of making, and metho of use thereof |
CN101797236B (zh) * | 2010-03-23 | 2012-05-23 | 西南大学 | 重酒石酸卡巴拉汀口腔崩解片及其制备方法 |
CA2800176C (en) | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
AU2012253834B2 (en) * | 2011-05-06 | 2016-06-16 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Sustained release paracetamol formulations |
CN109908099B (zh) | 2011-05-13 | 2021-10-29 | Eb Ip希博里塔布斯有限责任公司 | 药物递送系统 |
US8524664B2 (en) | 2011-06-02 | 2013-09-03 | Colorado Seminary, Which owns and Operates The Univeristy of Denver | Methods of treating overproduction of cortisol using ACTH antagonist peptides |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
JP6285865B2 (ja) | 2011-11-14 | 2018-02-28 | アルファシグマ ソシエタ ペル アチオニ | うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法 |
CN104768540A (zh) | 2012-09-05 | 2015-07-08 | 才思制药公司 | 抗胆碱能神经保护组合物和方法 |
WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
ES2888074T3 (es) | 2013-08-16 | 2021-12-30 | Univ Maastricht | Tratamiento del deterioro cognitivo con inhibidor de PDE4 |
WO2015136446A1 (en) | 2014-03-11 | 2015-09-17 | Nestec S.A. | Methods for selecting antidepressant drug therapy to treat depression |
CN103877063A (zh) * | 2014-03-24 | 2014-06-25 | 张绪伟 | 一种重酒石酸卡巴拉汀胶囊及其制备方法 |
JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
KR101990951B1 (ko) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | 리바스티그민 함유 서방출 의약조성물 |
CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
WO2019039836A2 (ko) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
KR20190036370A (ko) | 2017-09-27 | 2019-04-04 | 서원대학교산학협력단 | 약물의 서방성 제형을 위한 약물전달체 |
AU2019313324A1 (en) | 2018-07-30 | 2021-02-04 | Biothea Pharma, Inc. | Crystalline epinephrine malonate salt |
CN112546037A (zh) * | 2020-12-08 | 2021-03-26 | 苏州大学 | 卡巴拉汀在制备抗辐射药中的应用 |
CN113398273B (zh) * | 2021-05-14 | 2022-07-19 | 广西壮族自治区中国科学院广西植物研究所 | 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
USRE34990E (en) * | 1986-08-07 | 1995-07-04 | Ciba-Geigy Corporation | Oral therapeutic system having systemic action |
HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
DE3805744C2 (de) * | 1987-03-04 | 1999-09-23 | Novartis Ag | Phenylcarbamate zur Hemmung der Acetylcholinesterase |
US5472710A (en) * | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
DE3922167A1 (de) * | 1988-04-16 | 1991-01-17 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung |
US5262173A (en) * | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
DK0621032T3 (da) * | 1993-04-23 | 2000-10-23 | Novartis Ag | Lægemiddelform med reguleret afgivelse |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
GB9701695D0 (en) | 1997-01-28 | 1997-03-19 | De Beers Ind Diamond | Insert for an abrasive tool |
DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
GB9800526D0 (en) * | 1998-01-12 | 1998-03-11 | Ciba Geigy Ag | Organic compounds |
KR100603900B1 (ko) | 1998-10-01 | 2006-07-25 | 노파르티스 아게 | 신규의 서방성 경구 제제 |
US6534541B1 (en) | 1999-10-19 | 2003-03-18 | Novartis Ag | Treatment of ocular disorders |
-
1999
- 1999-10-01 KR KR1020017003384A patent/KR100603900B1/ko not_active IP Right Cessation
- 1999-10-01 ES ES99950595T patent/ES2237163T3/es not_active Expired - Lifetime
- 1999-10-01 CN CN99811633A patent/CN1406126A/zh active Pending
- 1999-10-01 EP EP99950595A patent/EP1121104B1/en not_active Expired - Lifetime
- 1999-10-01 BR BR9914251-1A patent/BR9914251A/pt not_active Application Discontinuation
- 1999-10-01 IL IL14176299A patent/IL141762A0/xx unknown
- 1999-10-01 CZ CZ20011155A patent/CZ302888B6/cs not_active IP Right Cessation
- 1999-10-01 SK SK439-2001A patent/SK285250B6/sk not_active IP Right Cessation
- 1999-10-01 AT AT99950595T patent/ATE286725T1/de active
- 1999-10-01 NZ NZ510683A patent/NZ510683A/en not_active IP Right Cessation
- 1999-10-01 ID IDW20010671A patent/ID27504A/id unknown
- 1999-10-01 HU HU0103883A patent/HUP0103883A3/hu unknown
- 1999-10-01 AU AU63321/99A patent/AU764866B2/en not_active Ceased
- 1999-10-01 PL PL348734A patent/PL196945B1/pl not_active IP Right Cessation
- 1999-10-01 PT PT99950595T patent/PT1121104E/pt unknown
- 1999-10-01 CA CA002342340A patent/CA2342340C/en not_active Expired - Fee Related
- 1999-10-01 JP JP2000573347A patent/JP4012689B2/ja not_active Expired - Fee Related
- 1999-10-01 DE DE69923200T patent/DE69923200T2/de not_active Expired - Lifetime
- 1999-10-01 TR TR2001/00931T patent/TR200100931T2/xx unknown
- 1999-10-01 WO PCT/EP1999/007298 patent/WO2000019985A2/en not_active Application Discontinuation
-
2001
- 2001-03-01 IL IL141762A patent/IL141762A/en unknown
- 2001-03-22 NO NO20011471A patent/NO331689B1/no not_active IP Right Cessation
- 2001-03-27 US US09/818,690 patent/US20010033866A1/en not_active Abandoned
-
2002
- 2002-04-08 US US10/118,183 patent/US6565883B2/en not_active Expired - Fee Related
-
2003
- 2003-03-31 US US10/403,146 patent/US20030203025A1/en not_active Abandoned
- 2003-07-09 HK HK03104925.9A patent/HK1052473A1/zh unknown
-
2005
- 2005-04-14 US US11/105,967 patent/US20050175706A1/en not_active Abandoned
-
2006
- 2006-11-03 US US11/592,853 patent/US20070053982A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1121104E (pt) | Novas formulacoes orais de libertacao controlada | |
AP1954A (en) | Controlled release compositions comprising nimesulide. | |
EE04901B1 (et) | Peroraalne farmatseutiline pikendatud vabanemisega annusvorm | |
CY2007031I1 (el) | Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης | |
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
TR200003787A3 (tr) | Kararli yavas salimli oral dozaj bilesimi. | |
NO20003219L (no) | Oral farmasøytisk doseringsform med pulsert frigivningsvirkning | |
BR9810495A (pt) | Composição farmacêutica | |
DE69822172D1 (de) | Levosimendanhaltige oral anzuwendende arzneizusammensetzungen | |
ATE291914T1 (de) | Zolmitriptanhaltige arzneizusammensetzungen | |
SE9700885D0 (sv) | New pharmaceutical formulation | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
RS50298B (sr) | Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina | |
HRP20020893A2 (en) | Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases | |
MY128759A (en) | Oral controlled release formulations | |
ES2171669T3 (es) | Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion. | |
DE50015195D1 (de) | Feste paroxetin enthaltende zubereitungen | |
DE60234604D1 (de) | Orale dosierungsform enthaltend einen therapeutischen wirkstoff und einen gegenwirdenden wirkstoff | |
MY145885A (en) | Controlled release formulations for oral administration | |
DK1237551T3 (da) | Farmaceutiske formuleringer indeholdende zolmitriptan |